PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

Arrowstreet Capital Limited Partnership purchased a new stake in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 241,430 shares of the biopharmaceutical company's stock, valued at approximately $1,668,000. Arrowstreet Capital Limited Partnership owned approximately

Vanda Pharmaceuticals (NASDAQ: VNDA) reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it expects operating expenses to begin declining late this year, with more

Vanda Pharmaceuticals NASDAQ: VNDA reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it expects operating expenses to begin declining late this year, with more substantial reductions anticipated in 2027.

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.

Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%  Full-year 2026 total revenue guidance of $240-$290 million  Cash totaled $170.0 million as of June 30, 2026; expected to fund operations through at least the end of 2027  BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026  Quimilza™ (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026  NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026  Results for three Phase III clinical trials expected by end of 2026:  NEREUS™ (tradipitant) in vomiting in GLP-1,  VQW-765 in social anxiety disorder  HETLIOZ® (tasimelteon) in delayed sleep phase disorder  WASHINGTON, Aug. 5, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026.  "We are pleased with the continued strong growth of Fanapt and the enthusiastic early response to NEREUS as it becomes available to patients.

Conference Call and Webcast to Follow WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on Wednesday, August 5, 2026, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, August 5, 2026, during which management will discuss the second quarter 2026 financial results and other corporate activities.

WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP). This marks the first time the EMA has granted orphan drug designation recognition for a drug to treat GPP in the European Union (EU).

WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.